Related Experiment Video
Updated: Mar 24, 2026
Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay
Published on: June 30, 2023
Noninvasive tracer techniques to characterize angiogenesis
1Universitätsklinik für Nuklearmedizin, Medizinische Universität Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. roland.haubner@i-med.ac.at
Abstract:
Great efforts are being made to develop antiangiogenesis drugs for treatment of cancer as well as other diseases. Some of the compounds are already in clinical trials. Imaging techniques allowing noninvasive monitoring of corresponding molecular processes can provide helpful information for planning and controlling corresponding therapeutic approaches but will also be of interest for basic science. Current nuclear medicine techniques focus on the development of tracer targeting the vascular endothelial growth factor (VEGF) system, matrix metalloproteinases (MMP), the ED-B domain of a fibronectin isoform, and the integrin alphavbeta3. In this chapter, the recent tracer developments as well as the preclinical and the clinical evaluations are summarized and the potential of the different approaches to characterize angiogenesis are discussed.
Insights
Researchers are developing anti-angiogenesis drugs and advanced imaging tracers to monitor cancer treatment. Nuclear medicine techniques targeting VEGF, MMPs, and integrins show promise for evaluating therapeutic effectiveness.
Area of Science:
- Biomedical imaging
- Oncology
- Pharmacology
Background:
- Angiogenesis is crucial in cancer and other diseases, driving the development of anti-angiogenesis drugs.
- Noninvasive imaging is essential for monitoring therapeutic responses to anti-angiogenesis treatments.
- Current research focuses on nuclear medicine tracers for molecular targets involved in angiogenesis.
Purpose of the Study:
- To summarize recent developments in nuclear medicine tracers for angiogenesis.
- To review preclinical and clinical evaluations of these tracers.
- To discuss the potential of various approaches in characterizing angiogenesis.
Main Methods:
- Development of novel nuclear medicine tracers.
- Targeting key molecular systems: vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), ED-B fibronectin, and integrin alphavbeta3.
- Preclinical and clinical evaluation of tracer efficacy and safety.
Main Results:
- Several tracers targeting VEGF, MMPs, ED-B, and integrin alphavbeta3 have been developed.
- These tracers have undergone preclinical and clinical assessments.
- The potential of these imaging agents for characterizing angiogenesis is under investigation.
Conclusions:
- Nuclear medicine tracers offer a noninvasive method to monitor angiogenesis.
- Targeted tracers provide valuable insights for anti-angiogenesis drug development and patient management.
- Further research is needed to fully realize the clinical utility of these imaging techniques.
